Protagonist Therapeutics (PTGX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.38 (+0.91%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Key Insights

Critical company metrics and information
  • Share Price

    $42.06
  • Market Cap

    $2.51 Billion
  • Total Outstanding Shares

    59.60 Million Shares
  • Total Employees

    126
  • Dividend

    No dividend
  • IPO Date

    August 11, 2016
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.protagonist-inc.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-27.86 Million
Net Cash Flow From Financing Activities, Continuing$12.05 Million
Net Cash Flow, Continuing$-224.52 Million
Net Cash Flow From Operating Activities, Continuing$-27.86 Million
Net Cash Flow$-224.52 Million
Net Cash Flow From Investing Activities$-208.71 Million
Net Cash Flow From Investing Activities, Continuing$-208.71 Million
Net Cash Flow From Financing Activities$12.05 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Basic Average Shares$61.77 Million
Diluted Earnings Per Share$0.54
Operating Income/Loss$-41.45 Million
Income/Loss From Continuing Operations Before Tax$-33.63 Million
Net Income/Loss Available To Common Stockholders, Basic$-33.21 Million
Net Income/Loss$-33.21 Million
Benefits Costs and Expenses$38.30 Million
Revenues$4.67 Million
Costs And Expenses$38.30 Million
Income Tax Expense/Benefit$420000.00
Preferred Stock Dividends And Other Adjustments$0.00
Other Operating Expenses$10.16 Million
Net Income/Loss Attributable To Parent$-33.21 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$46.13 Million
Basic Earnings Per Share$0.54
Income/Loss From Continuing Operations After Tax$-33.21 Million
Diluted Average Shares$61.77 Million
Research and Development$35.97 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Fixed Assets$2.47 Million
Equity Attributable To Parent$531.91 Million
Liabilities$71.94 Million
Current Assets$476.77 Million
Accounts Payable$3.05 Million
Current Liabilities$44.58 Million
Equity$531.91 Million
Other Current Liabilities$41.53 Million
Other Non-current Assets$124.62 Million
Noncurrent Liabilities$27.36 Million
Noncurrent Assets$127.09 Million
Liabilities And Equity$603.86 Million
Assets$603.86 Million
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.